Recent events
Recent events tied to this brand in public sources.
Back to profile15 entries
2026
Pennsylvania sues insulin makers and PBMs over alleged insulin price collusion
Pennsylvania sued Eli Lilly and Co., Novo Nordisk Inc., Sanofi-Aventis US LLC, and several PBMs, alleging that they colluded to raise insulin prices. The lawsuit seeks structural changes, restitution, and financial penalties.
2026
Florida AG sues Prime Therapeutics and Express Scripts over alleged price fixing
Florida Attorney General James Uthmeier announced a lawsuit alleging that Prime Therapeutics and Express Scripts formed an illegal horizontal price-fixing agreement in December 2019 to suppress pharmacy reimbursement rates, with the alleged collusion beginning in April 2020 and impacting 80 percent of branded and 70 percent of generic drugs, resulting in $2.5 billion in savings for Prime while forcing independent pharmacies to dispense medication at a loss. The lawsuit charges the companies with antitrust violations, unfair competition, and unjust enrichment.
2026
Florida sues Prime Therapeutics and Express Scripts over alleged drug price fixing
Florida Attorney General James Uthmeier filed a lawsuit alleging that Prime Therapeutics and Express Scripts entered into an illegal agreement to fix prices on otherwise affordable drugs, citing a December 2019 collaboration in which Prime adopted Express Scripts' lower reimbursement rates.
2024
Oklahoma files insulin-pricing lawsuit against drug manufacturers and pharmacy benefit managers
Oklahoma Attorney General Gentner Drummond filed a lawsuit against named drug manufacturers and pharmacy benefit managers, alleging unfair insulin prices and claiming manufacturers and PBMs coordinated to control drug prices and purchasing behavior. The allegations are not presented as a court determination.
2024
Baltimore sues insulin manufacturers and pharmacy benefit managers over pricing
The City of Baltimore filed a federal racketeering lawsuit against Eli Lilly, Sanofi, Novo Nordisk, CVS, Express Scripts and OptumRx, alleging that the companies conspired to artificially raise insulin prices. The lawsuit also raises civil conspiracy, antitrust and unjust enrichment claims; the allegations are not determinations of wrongdoing. Eli Lilly called the complaint “baseless”; CVS and Novo Nordisk said they would defend against the claims, Sanofi said its pricing practices complied with the law, and Optum said the lawsuit was without merit.
2023
Arizona files insulin pricing lawsuit
Arizona Attorney General Kris Mayes filed a lawsuit on November 27 against pharmaceutical manufacturers and pharmacy benefit managers, alleging they inflated prices for insulin and other diabetes drugs in violation of the Arizona Consumer Fraud Act. The named defendants include CVS Caremark, Express Scripts, OptumRx, Novo Nordisk, Sanofi-Aventis U.S. LLC, and Eli Lilly and Company.
2023
Los Angeles County sues Express Scripts and OptumRx over alleged opioid-related conduct
Los Angeles County sued Express Scripts and OptumRx, alleging that they colluded with drug manufacturers to promote dangerously addictive opioids as a safe and moderate pain treatment option. The allegations are claims in the lawsuit, not findings established in the source.
2023
AHF announces protest against Cigna over Express Scripts practices
AIDS Healthcare Foundation announced a protest against Cigna and its pharmacy benefit manager Express Scripts, alleging that Express Scripts’ practices disrupt patient care and harm access to patients’ chosen pharmacies. The protest was scheduled for August 24, 2023.
2023
Cleveland sues insulin companies over alleged pricing scheme
The city of Cleveland sued drug makers, pharmacy benefit managers, and corporate conglomerates, alleging a conspiracy to overcharge the city for insulin. Named companies include Eli Lilly, Express Scripts, and CVS; the claims are allegations, and CVS Health rejects the claims against it.
2023
Express Scripts unveils pharmacy benefit solutions
Express Scripts unveiled the Copay Assurance Plan, which caps consumers’ out-of-pocket drug costs, and announced ClearCareRx, an offering providing clients with more transparent costs and a flat per-member-per-month fee.
2022
Express Scripts and others sued over pharmacy billing
A patient and his minor child filed a lawsuit against Express Scripts Inc., Accredo Health Group Inc., and the National Recovery Agency, alleging violations of federal and California debt collection laws related to pharmacy billing. The plaintiff alleges that the defendants sought copayments directly instead of billing a copay assistance program and refused to send an emergency dose for the child.
2020
Lackie Drug Store sues pharmacy benefit managers over alleged anticompetitive practices
Lackie Drug Store Inc. filed a case in Lonoke County Circuit Court alleging that pharmacy benefit managers, including CVS Health Corporation and Caremark entities, used reimbursement methodologies and practices that were anticompetitive. The allegations include withholding Maximum Allowable Cost information and conspiracy regarding pricing rates; the source reports allegations, not a determination.
2020
Cigna and Express Scripts sue former employee
Cigna Corporation and its subsidiary Express Scripts filed suit against a former employee, accusing him of theft of trade secrets and violation of confidentiality agreements. The claims are allegations in the complaint.
2019
Harris County files insulin price-fixing lawsuit
Harris County sued insulin manufacturers Eli Lilly, Novo Nordisk and Sanofi, along with pharmaceutical benefit managers Aetna Rx, CVS Caremark, Express Scripts and OptumRx, alleging they colluded to drive up insulin prices. The county seeks to recover more than $27 million it says it has paid to the companies.
2019
Jury verdict favors Express Scripts in Micro Focus licensing dispute
A federal jury rejected Micro Focus’s arguments in its software-license dispute with Express Scripts, and the article says the jury construed the ambiguous terms against Micro Focus and found Express Scripts’ interpretation most reasonable.